open access

Vol 12, No 1 (2016)
Case report
Published online: 2016-05-02
Get Citation

Late recurrence of breast cancer in a patient with BRCA1 mutation and subsequent radical treatment for colorectal and endometrial cancer — a case report

Karolina Hofman-Pyka, Andrzej Witkoś, Teresa Lisik, Ewa Nowakowska-Zajdel
Oncol Clin Pract 2016;12(1):19-32.

open access

Vol 12, No 1 (2016)
CASE REPORT
Published online: 2016-05-02

Abstract

Breast cancer is the most common malignancy in women. Hereditary predisposition is found in 5–10% women with breast cancer and most frequently depends on BRCA1 and BRCA2 mutations. In BRCA1 mutation carriers there is a 56–84% risk of breast cancer and a 36–63% risk of ovarian cancer, while in BRCA2 it is 45–85% and 10–27%, respectively. In both groups there is a 2–3-fold risk of other malignancies. We present a case of a BRCA1 mutation carrier with late relapse of breast cancer after radical treatment for two other malignancies (colorectal and endometrial cancer).

Abstract

Breast cancer is the most common malignancy in women. Hereditary predisposition is found in 5–10% women with breast cancer and most frequently depends on BRCA1 and BRCA2 mutations. In BRCA1 mutation carriers there is a 56–84% risk of breast cancer and a 36–63% risk of ovarian cancer, while in BRCA2 it is 45–85% and 10–27%, respectively. In both groups there is a 2–3-fold risk of other malignancies. We present a case of a BRCA1 mutation carrier with late relapse of breast cancer after radical treatment for two other malignancies (colorectal and endometrial cancer).

Get Citation

Keywords

breast cancer; BRCA1/2 gene mutations; late relapse; colorectal cancer; endometrial cancer

About this article
Title

Late recurrence of breast cancer in a patient with BRCA1 mutation and subsequent radical treatment for colorectal and endometrial cancer — a case report

Journal

Oncology in Clinical Practice

Issue

Vol 12, No 1 (2016)

Article type

Case report

Pages

19-32

Published online

2016-05-02

Bibliographic record

Oncol Clin Pract 2016;12(1):19-32.

Keywords

breast cancer
BRCA1/2 gene mutations
late relapse
colorectal cancer
endometrial cancer

Authors

Karolina Hofman-Pyka
Andrzej Witkoś
Teresa Lisik
Ewa Nowakowska-Zajdel

References (19)
  1. Stewart BW, Wild C. World Cancer Report 2014. IARC Nonserial Publication. 2014: 363–374.
  2. Gronwald J, Byrski T, Huzarski T. Genetyka kliniczna raka piersi i jajnika. In: Lubiński J, Byrski T, Huzarski T. ed. Genetyka kliniczna nowotworów 2012. Pomorski Uniwersytet Medyczny, Szczecin 2012: 69–92.
  3. Jassem J, Krzakowski M, Bobek-Billewicz B. Rak piersi. In: Krzakowski M, Warzocha K. ed. Zalecenia postępowania diagnostyczno-terapeutycznego w nowotworach złośliwych 2013 rok. Via Medica, Gdańsk 2013: 211–264.
  4. Jassem J. Rak piersi. In: Krzakowski M, Potemski P, Warzocha K, Wysocki P. ed. Onkologia Kliniczna. Via Medica, Gdańsk 2015: 643–645.
  5. Górski B, Cybulski C, Huzarski T, et al. Breast cancer predisposing alleles in Poland. Breast Cancer Res Treat. 2005; 92(1): 19–24.
  6. Gronwald J, Huzarski T, Byrski B, et al. Cancer risks in first degree relatives of BRCA1 mutation carriers: effects of mutation and proband disease status. J Med Genet. 2006; 43(5): 424–428.
  7. Brożek I, Limon J. Poradnictwo genetyczne w dziedzicznym raku piersi. In: Jassem J, Krzakowski M. ed. Rak piersi. Praktyczny przewodnik dla lekarzy, wydanie II. Via Medica, Gdańsk 2014: 21–23.
  8. Cavanagh H, Rogers KMA. The role of BRCA1 and BRCA2 mutations in prostate, pancreatic and stomach cancers. Hered Cancer Clin Pract. 2015; 13(1): 16.
  9. Dawood S, Broglio K, Esteva FJ, et al. Survival among women with triple receptor-negative breast cancer and brain metastases. Ann Oncol. 2009; 20(4): 621–627.
  10. Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007; 13(15 Pt 1): 4429–4434.
  11. Metcalfe K, Lynch HT, Ghadirian P, et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2004; 22(12): 2328–2335.
  12. Menes TS, Terry MB, Goldgar D, et al. Second primary breast cancer in BRCA1 and BRCA2 mutation carriers: 10-year cumulative incidence in the Breast Cancer Family Registry. Breast Cancer Res Treat. 2015; 151(3): 653–660.
  13. Molina-Montes E, Pérez-Nevot B, Pollán M, et al. Cumulative risk of second primary contralateral breast cancer in BRCA1/BRCA2 mutation carriers with a first breast cancer: A systematic review and meta-analysis. Breast. 2014; 23(6): 721–742.
  14. Kirchhoff T, Satagopan JM, Kauff ND, et al. Frequency of BRCA1 and BRCA2 mutations in unselected Ashkenazi Jewish patients with colorectal cancer. J Natl Cancer Inst. 2004; 96(1): 68–70.
  15. Niell BL, Rennert G, Bonner JD, et al. BRCA1 and BRCA2 founder mutations and the risk of colorectal cancer. J Natl Cancer Inst. 2004; 96(1): 15–21.
  16. Phelan CM, Iqbal J, Lynch HT, et al. Hereditary Breast Cancer Study Group. Incidence of colorectal cancer in BRCA1 and BRCA2 mutation carriers: results from a follow-up study. Br J Cancer. 2014; 110(2): 530–534.
  17. Beiner ME, Finch A, Rosen B, et al. Hereditary Ovarian Cancer Clinical Study Group. The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study. Gynecol Oncol. 2007; 104(1): 7–10.
  18. Segev Y, Iqbal J, Lubinski J, et al. Hereditary Breast Cancer Study Group. The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations: an international prospective cohort study. Gynecol Oncol. 2013; 130(1): 127–131.
  19. Bruchim I, Amichay K, Kidron D, et al. BRCA1/2 germline mutations in Jewish patients with uterine serous carcinoma. Int J Gynecol Cancer. 2010; 20(7): 1148–1153.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl